Others

Haihe Biopharma's Liporaxel Wins NMPA Approval for HER2‑Negative Breast Cancer – World's First Oral Paclitaxel Expands into Second Indication in China
3SBioHaihe Biopharma

Haihe Biopharma’s Liporaxel Wins NMPA Approval for HER2‑Negative Breast Cancer – World’s First Oral Paclitaxel Expands into Second Indication in China

Shanghai Haihe Biopharma Co., Ltd, a partner of 3SBio Inc. (HKG: 1530), announced that its paclitaxel oral solution (registered trademark: Liporaxel; development code: RMX3001/DHP107), developed in collaboration with South Korea‑based…

Humanwell Healthcare Subsidiary Wins FDA ANDA Approval for Diltiazem Hydrochloride Tablets – Expanding U.S. Generic Cardiovascular Portfolio

Humanwell Healthcare Subsidiary Wins FDA ANDA Approval for Diltiazem Hydrochloride Tablets – Expanding U.S. Generic Cardiovascular Portfolio

AbbVie Secures Dual FDA Breakthrough Therapy Designations for Temab‑A in Colorectal and Lung Cancers – Next‑Gen c‑Met ADC Advances

AbbVie Secures Dual FDA Breakthrough Therapy Designations for Temab‑A in Colorectal and Lung Cancers – Next‑Gen c‑Met ADC Advances

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Hengrui PharmaceuticalsHKG: 1276

Hengrui’s SHR-9839 + HRS-4642 Combo Cleared for Advanced CRC Trials

Johnson & Johnson Strikes Tariff Exemption Deal with Trump Administration
J&JJohnson & Johnson

Johnson & Johnson Strikes Tariff Exemption Deal with Trump Administration

Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee

Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee

Novo Nordisk CagriSema Pediatric Obesity Trial to Enroll 460 Children
Novo NordiskNYSE: NVO

Novo Nordisk CagriSema Pediatric Obesity Trial to Enroll 460 Children

Show More